Chandan Verma

Contact

• workRoom W/E/1517 E Floor, West Block, QMC
  Queen's Medical Centre
  Nottingham
  NG7 2UH
  UK
• work0115 82 31168
• fax0115 82 31160
• chandan.verma@nottingham.ac.uk
• www.nottingham.ac.uk

Research Summary

Immunotherapy Clinical Trials, Cancer Vaccines: hTERT (Human Telomerase Reverse Transcriptase) Impact of Chemotherapeutic Drugs on Host Defences in women with Breast Cancer Regulatory T… read more

Recent Publications

• 2011. Therapy and Host defences. In: Essential Immunology for Surgeons Oxford University Press. 450 pages
• ALOYSIUS MM, MC KECHNIE AJ, ROBINS RA, VERMA C, EREMIN JM, FARZANEH F, HABIB NA, BHALLA J, HARDWICK NR, SATTHAPORN S, SREENIVASAN T, EL-SHEEMY M and EREMIN O, 2009. Generation In Vivo Of Peptide-Specific Cytotoxic T Cells And Presence Of Regulatory T Cells During Vaccination With Htert (Class I And Ii) Peptide-Pulsed Dcs. Journal Of Translational Medicine. 7, 18
• SATTHAPORN, SUKCHAI, ALOYSIUS, MARK M, ROBINS, RICHARD A, VERMA, CHANDAN, CHUTHAPISITH, SUEBWONG, MCKECHNIE, ALASDAIR J, EL-SHEEMY, MOHAMAD, VASSANASIRI, WICHAI, VALERIO, DAVID, CLARK, DAVID and JIBRIL,, 2008. Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha. BMC immunology. 9, 32
• MARK ALOYSIUS, RICHARD ADRIAN ROBINS, CHANDAN VERMA AND OLEG EREMIN, 2008. Targeting Human Telomerase Reverse Transcriptase: A Promising Anticancer Immunotherapeutic Approach Cancer and Chemotherapy Reviews;. 3(4),

• View all publications

Current Research

• Immunotherapy Clinical Trials, Cancer Vaccines: hTERT (Human Telomerase Reverse Transcriptase)
• Impact of Chemotherapeutic Drugs on Host Defences in women with Breast Cancer
• Regulatory T cells: Tregs, CTLA-4, Myeloid/Granulocytic Derived Suppressor Cells
• Dendritic cells
• NK/NKT cells
• T cells

Past Research

Immunotherapy Clinical Trials, Cancer Vaccines: hTERT (Human Telomerase Reverse Transcriptase)

Future Research

Immunotherapy Clinical Trials, Cancer Vaccines: hTERT (Human Telomerase Reverse Transcriptase)

• 2011. Therapy and Host defences. In: Essential Immunology for Surgeons Oxford University Press. 450 pages
• ALOYSIUS MM, MC KECHNIE AJ, ROBINS RA, VERMA C, EREMIN JM, FARZANEH F, HABIB NA, BHALLA J, HARDWICK NR, SATTHAPORN S, SREENIVASAN T, EL-SHEEMY M and EREMIN O, 2009. Generation In Vivo Of Peptide-Specific Cytotoxic T Cells And Presence Of Regulatory T Cells During Vaccination With Htert (Class I And Ii) Peptide-Pulsed Dcs. Journal Of Translational Medicine. 7, 18
• SATTHAPORN, SUKCHAI, ALOYSIUS, MARK M, ROBINS, RICHARD A, VERMA, CHANDAN, CHUTHAPISITH, SUEBWONG, MCKECHNIE, ALASDAIR J, EL-SHEEMY, MOHAMAD, VASSANASIRI, WICHAI, VALERIO, DAVID, CLARK, DAVID and JIBRIL,, 2008. Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha. BMC immunology. 9, 32
• MARK ALOYSIUS, RICHARD ADRIAN ROBINS, CHANDAN VERMA AND OLEG EREMIN, 2008. Targeting Human Telomerase Reverse Transcriptase: A Promising Anticancer Immunotherapeutic Approach Cancer and Chemotherapy Reviews;. 3(4),